Jean-Philippe Hauzeur1,2, Viviane De Maertelaer3, Etienne Baudoux4, Michel Malaise5, Yves Beguin4, Valérie Gangji6. 1. Department of Rheumatology, CHU de Liège, University of Liège, B 4000, Liège, Belgium. jean-philippe@hauzeur.org. 2. Department of Rheumatology and Physical Medicine, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, 1070, Brussels, Belgium. jean-philippe@hauzeur.org. 3. Department of Biostatistics and Medical Informatics & IRIBHM, School of Medicine, Université Libre de Bruxelles, ULB, 808 route de Lennik, 1070, Brussels, Belgium. 4. Laboratory of Cell and Gene Therapy, CHU de Liège, University of Liège, Liège, Belgium. 5. Department of Rheumatology, CHU de Liège, University of Liège, B 4000, Liège, Belgium. 6. Department of Rheumatology and Physical Medicine, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, 1070, Brussels, Belgium.
Abstract
PURPOSE: The fracture stage of non-traumatic osteonecrosis (ON stage 3) of the femoral head (ONFH) has an unfavourable prognosis frequently requiring total hip replacement (THR). The percentage could be lowered after core decompression. In earlier non-fracture ON stages, implantation of autologous bone marrow aspirate concentrate (BMAC) improved the effect of core decompression. The purpose was to evaluate the effect of BMAC in addition to core decompression in stage 3 ONFH. METHODS: A double blind RCT was conducted comparing two groups: core decompression plus saline injection or core decompression plus BMAC implantation. Both patients and assessors were blinded to the treatment assignments. Evaluations were done at baseline, three, six, 12, and 24 months, including pain (VAS), WOMAC, side-effects, radiological evolution including ARCO subclassifications, together with possible THR requirement. The primary endpoint was the need for THR. The second endpoints included the clinical symptoms such as pain and functional ability and the progression of the ON lesions as well as the appearance of osteoarthritis features (ARCO stage 4). Both groups included 23 hips (19 patients). RESULTS: No differences were found between the groups for THR requirements, clinical tests, and radiological evolution. In both groups, 15/23 hips needed THR. The radiological evolution of the ONFH lesions in term of location, extension, surface collapse, and dome depression was moderate in both groups and was not correlated with the need of THR. CONCLUSIONS: Implantation of BMAC after core decompression did not produce any improvement of the evolution of ONFH stage 3. Level of evidence I.
RCT Entities:
PURPOSE: The fracture stage of non-traumatic osteonecrosis (ON stage 3) of the femoral head (ONFH) has an unfavourable prognosis frequently requiring total hip replacement (THR). The percentage could be lowered after core decompression. In earlier non-fracture ON stages, implantation of autologous bone marrow aspirate concentrate (BMAC) improved the effect of core decompression. The purpose was to evaluate the effect of BMAC in addition to core decompression in stage 3 ONFH. METHODS: A double blind RCT was conducted comparing two groups: core decompression plus saline injection or core decompression plus BMAC implantation. Both patients and assessors were blinded to the treatment assignments. Evaluations were done at baseline, three, six, 12, and 24 months, including pain (VAS), WOMAC, side-effects, radiological evolution including ARCO subclassifications, together with possible THR requirement. The primary endpoint was the need for THR. The second endpoints included the clinical symptoms such as pain and functional ability and the progression of the ON lesions as well as the appearance of osteoarthritis features (ARCO stage 4). Both groups included 23 hips (19 patients). RESULTS: No differences were found between the groups for THR requirements, clinical tests, and radiological evolution. In both groups, 15/23 hips needed THR. The radiological evolution of the ONFH lesions in term of location, extension, surface collapse, and dome depression was moderate in both groups and was not correlated with the need of THR. CONCLUSIONS: Implantation of BMAC after core decompression did not produce any improvement of the evolution of ONFH stage 3. Level of evidence I.
Authors: Michael A Mont; German A Marulanda; Lynne C Jones; Khaled J Saleh; Noah Gordon; David S Hungerford; Marvin E Steinberg Journal: J Bone Joint Surg Am Date: 2006-11 Impact factor: 5.284
Authors: Andreas Roth; Johannes Beckmann; Klaus Bohndorf; Christian Heiß; Marcus Jäger; Stefan Landgraeber; Uwe Maus; Ulrich Nöth; Klaus M Peters; Christof Rader; Stephan Reppenhagen; Ulrich Smolenski; Ina Kopp; Markus Tingart Journal: Orthopade Date: 2018-09 Impact factor: 1.087
Authors: Philippe Hernigou; Arnaud Dubory; Yasuhiro Homma; Isaac Guissou; Charles Henri Flouzat Lachaniette; Nathalie Chevallier; Hélène Rouard Journal: Int Orthop Date: 2018-05-09 Impact factor: 3.075
Authors: Michael A Mont; Hytham S Salem; Nicolas S Piuzzi; Stuart B Goodman; Lynne C Jones Journal: J Bone Joint Surg Am Date: 2020-06-17 Impact factor: 6.558